|
| 37023796 | Diabetic retinopathy screening integrated in a multidisciplinary diabetes care clinic: a pilot project. | Can J Ophthalmol | 2024 |
| 38082486 | Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD. | J Am Soc Nephrol | 2024 |
| 38015810 | Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes. | Diabetes | 2024 |
| 37801140 | Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. | Diabetologia | 2024 |
| 38036220 | Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes. | Diabetes Res Clin Pract | 2024 |
| 36394384 | Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. | Diabetes Obes Metab | 2023 |
| 37864578 | Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. | Eur Heart J | 2023 |
| 37805000 | Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. | Diabetes Res Clin Pract | 2023 |
| 37517546 | Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials. | Am J Kidney Dis | 2023 |
| 37616393 | Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes. | Diabetes Care | 2023 |
| 37616058 | Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients. | J Clin Invest | 2023 |
| 37531756 | Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal function. | J Diabetes Complications | 2023 |
| 35507146 | Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes. | Pediatr Nephrol | 2023 |
| 35378662 | Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon. | Sleep Breath | 2023 |
| 37060902 | Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. | Cell Metab | 2023 |
| 37184050 | Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. | Diabetes Obes Metab | 2023 |
| 37045710 | Tirzepatide decreases systolic and diastolic blood pressure. | Eur J Intern Med | 2023 |
| 37172207 | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3. | Diabetes Care | 2023 |
| 37003273 | Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. | Lancet Healthy Longev | 2023 |
| 37232058 | Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial. | Diabetes Obes Metab | 2023 |
| 37069970 | Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. | Kidney Int Rep | 2023 |
| 37364589 | People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. | Lancet Diabetes Endocrinol | 2023 |
| 37267479 | Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. | Diabetes Care | 2023 |
| 37200064 | Erratum. Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort. Diabetes 2023;72:496-510. | Diabetes | 2023 |
| 37265366 | Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway. | Kidney360 | 2023 |
| 37429523 | Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. | Can J Cardiol | 2023 |
| 37427762 | Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease. | Diabetes Obes Metab | 2023 |
| 36782093 | Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. | Diabetes Obes Metab | 2023 |
| 36738891 | Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. | Kidney Int | 2023 |
| 36801984 | Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. | Diabetes Care | 2023 |
| 36706745 | SGLT2 Inhibitors: The Sweet Success for Kidneys. | Annu Rev Med | 2023 |
| 36702781 | Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. | J Clin Endocrinol Metab | 2023 |
| 36726361 | Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. | Can J Kidney Health Dis | 2023 |
| 36657976 | Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort. | Diabetes | 2023 |
| 36594154 | Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. | Diabetes Obes Metab | 2023 |
| 36524239 | The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. | Expert Rev Cardiovasc Ther | 2023 |
| 36180335 | Associations Among Biomarkers of Inflammation, Tubular Injury and Lipid Metabolism With Gestational Diabetes Mellitus Status, Microalbuminuria and Retinopathy in the Microalbuminuria and Retinopathy in Gestational Diabetes Study. | Can J Diabetes | 2023 |
| 34273060 | Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. | Int Urol Nephrol | 2022 |
| 35478433 | Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. | Diabetes Obes Metab | 2022 |
| 35649722 | Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. | Clin J Am Soc Nephrol | 2022 |
| 35840519 | Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. | J Diabetes Complications | 2022 |
| 35603908 | Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. | Diabetes Obes Metab | 2022 |
| 35394821 | Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. | Circulation | 2022 |
| 35633439 | SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. | Curr Diab Rep | 2022 |
| 35718364 | Sex and Gender Related Differences in Diabetic Kidney Disease. | Semin Nephrol | 2022 |
| 35691283 | Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. | Am J Nephrol | 2022 |
| 35523653 | Aminoaciduria and metabolic dysregulation during diabetic ketoacidosis: Results from the diabetic kidney alarm (DKA) study. | J Diabetes Complications | 2022 |
| 35862082 | Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. | Circulation | 2022 |
| 35812300 | Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. | Kidney Int Rep | 2022 |
| 35445820 | Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. | Diabetologia | 2022 |